D01 Stock Overview
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Belite Bio, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$41.20 |
| 52 Week High | US$41.80 |
| 52 Week Low | US$29.50 |
| Beta | -1.53 |
| 1 Month Change | 13.50% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 3.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| D01 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.5% | 0.01% | 0.1% |
| 1Y | n/a | -19.6% | 9.1% |
Return vs Industry: Insufficient data to determine how D01 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how D01 performed against the German Market.
Price Volatility
| D01 volatility | |
|---|---|
| D01 Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: D01's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine D01's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 20 | Tom Lin | www.belitebio.com |
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes.
Belite Bio, Inc Fundamentals Summary
| D01 fundamental statistics | |
|---|---|
| Market cap | €1.22b |
| Earnings (TTM) | -€30.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-40.7x
P/E RatioIs D01 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| D01 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$32.61m |
| Earnings | -US$32.61m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did D01 perform over the long term?
See historical performance and comparison